secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001654954-24-001591
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics prices $9M public offering of common stock and warrants
--------------------------------------------------------------------------

- 1.6M shares or pre-funded warrants plus 3.2M common warrants at $5.65/unit.
- Gross proceeds ~$9M; net proceeds ~$8M after fees and expenses.
- Net proceeds to fund Phase 3 LEVEL trial of oral levosimendan in PH-HFpEF.
- Roth Capital Partners acted as exclusive placement agent; offering closed Feb 12, 2024.
- Post-offering shares outstanding: 1,766,023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001591/0001654954-24-001591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001591/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-001591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer